[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367333-105":59,"doc-detail-367333-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","therapeutic-potential-of-fapi-rlt-in-oncology-a-systematic-review","Therapeutic potential of FAPI RLT in oncology - A systematic review","","This systematic review evaluates the safety and efficacy of fibroblast activation protein inhibitor (FAPI) radioligand therapy (RLT) across epithelial neoplasms. Searches of PubMed, Web of Science, and Scopus were conducted up to Jan 4, 2025. Twenty-seven studies with 144 patients were included: [177Lu]Lu-FAPI was used in 21 studies (95 patients, median 6.8 GBq/cycle), with limited grade 3–4 toxicity. Disease control varied by study. [90Y]Y-FAPI, [213Bi]Bi-FAPI-46, and dual radionuclide approaches were also reported, supporting short-term promise while long-term evidence remains limited.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-potential-of-fapi-rlt-in-oncology-a-systematic-review/367333/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-potential-of-fapi-rlt-in-oncology-a-systematic-review/367333.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the goal of this systematic review on FAPI radioligand therapy (RLT)?","Question",{"text":113,"@type":114},"To assess the safety and efficacy of FAPI RLT for various epithelial neoplasms.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How many studies and patients were included, and what radionuclides were most commonly used?",{"text":118,"@type":114},"Twenty-seven studies with 144 patients were included. [177Lu]Lu-FAPI was used in 21 studies, while [90Y]Y-FAPI and other radionuclides like [213Bi]Bi-FAPI-46 and [153Sm]Sm-FAPI were also reported.",{"name":120,"@type":111,"acceptedAnswer":121},"What safety findings are reported for [177Lu]Lu-FAPI?",{"text":122,"@type":114},"Only three studies documented a total of six patients with grade 3 or 4 toxicity after [177Lu]Lu-FAPI RLT.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367333,1790659161,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Ivyspring  \nInternational Publisher  \nReview  \nTheranostics  \n2025; 15(9): 4084-4100. doi: 10.7150/thno.106108  \nTherapeutic potential of FAPI RLT in oncology: A systematic review  \nSaad Ruzzeh1; Ahmed Saad Abdlkadir1; Diana Paez2; Keon W. Kang3,4,5,6; Tadashi Watabe7,8; Serin Moghrabi1; Andrew M. Scott9,10,11; Akram Al-Ibraheem1,12􀀍  \n1. Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Amman, 11941, Jordan.  \n2. Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.  \n3. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.  \n4. Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Republic of Korea.  \n5. Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.  \n6. Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Republic of Korea.  \n7. Department of Radiology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.  \n8. Institute for Radiation Sciences, Osaka University, Osaka 565-0871, Japan.  \n9. Department of Molecular Imaging and Therapy, Austin Health, 3084 Heidelberg, Australia.  \n10. Department of Medicine, University of Melbourne, 1853 Melbourne, Australia.  \n11. Olivia Newton-John Cancer Research Institute, and La Trobe University, 3084 Heidelberg, Australia.  \n12. School of Medicine, The University of Jordan, Amman 11942, Jordan.  \n􀀍 Corresponding authors: Akram Al-Ibraheem, MD, FRCP, FEBNM, FANMB, FRCPE, Department of Nuclear Medicine, King Hussein Cancer Center (KHCC), Queen Rania Street Al Jubeiha, Amman, Jordan, 11942. E-mail: [aibraheem@khcc.jo](aibraheem@khcc.jo), [akramalibrahim@gmail.com](akramalibrahim@gmail.com) (ORCID: 0000-0002-0978).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.10.31; Accepted: 2025.02.07; Published: 2025.03.10  \nAbstract  \nRationale: This systematic review aims to examine the safety and efficacy of fibroblast activation protein inhibitor (FAPI) radioligand therapy (RLT) for various epithelial neoplasms.  \nMethods: PubMed, Web of Science, and Scopus databases were searched up to Jan 4, 2025, for studies involving FAPI RLT in various cancers. Data extraction focused on exploring safety and efficacy of FAPIRLT.  \nResults: Overall, 27 studies involving a total of 144 patients who received FAPI RLT were included in this systematic review. [177Lu]Lu-FAPI was employed in 21 studies, with 225 cycles administered to 95 patients at a median dose of 6.8 GBq/cycle. Six non-randomized clinical investigations using [177Lu]Lu-FAPI reported disease control rates ranging from 18.2% to 83.3% . Only three studies documented a cumulative total of six patients who experienced grade 3 or 4 toxicity post [177Lu]Lu-FAPIRLT. Of 16 case reports utilizing [177Lu]Lu-FAPI, nine achieved disease control across various cancer types, with no reported adverse events. Four studies employed [90Y]Y-FAPI, totaling 103 cycles in 42 patients at a median dose of 6.7 GBq/cycle. Three non-randomized clinical investigations reported disease control rates of 50% to 82%, with two studies documenting eight high-grade toxicity events. Furthermore, a successful administration of [90Y]Y-FAPI was employed in a single reported case involving multiple primary neoplasms with no reported adverse events. However, the patient did not achieve disease control post [90Y]Y-FAPI. A cohort study utilized 53 [213Bi]Bi-FAPI-46 injections following a fractionated dose regimen in six cancer patients, achieving a 33.3% disease control rate without reported adverse events. One case report des","cbCaimaOxp9bmZtQ","https://ap.wps.com/l/cbCaimaOxp9bmZtQ","pdf",4141754,17,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is the goal of this systematic review on FAPI radioligand therapy (RLT)?\",\"answer\":\"To assess the safety and efficacy of FAPI RLT for various epithelial neoplasms.\"},{\"question\":\"How many studies and patients were included, and what radionuclides were most commonly used?\",\"answer\":\"Twenty-seven studies with 144 patients were included. [177Lu]Lu-FAPI was used in 21 studies, while [90Y]Y-FAPI and other radionuclides like [213Bi]Bi-FAPI-46 and [153Sm]Sm-FAPI were also reported.\"},{\"question\":\"What safety findings are reported for [177Lu]Lu-FAPI?\",\"answer\":\"Only three studies documented a total of six patients with grade 3 or 4 toxicity after [177Lu]Lu-FAPI RLT.\"}]","Therapeutic potential of FAPI RLT in oncology - A systematic review | PDF",1790170325,43]